Home/ Stocks/ ATYR

aTyr Pharma, Inc. Common Stock

ATYR XNAS

$0.51 +0.01 (+1.35%) ▲ 15-min delayed

Open

$0.50

High

$0.52

Low

$0.50

Volume

369.8K

Market Cap

$49.22M

About aTyr Pharma, Inc. Common Stock

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 58 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-10,792,000	$-0.11
FY 2025	$190.0K	$-74,123,000	$-0.80
Q3 2025	$190.0K	$-25,746,000	$-0.26
Q2 2025	$0	$-19,532,000	$-0.22

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for ATYR yet. Check out our latest market news or earnings calendar.

Get ATYR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on aTyr Pharma, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.